- AstraZeneca Pharma India’s Q4 FY26 net profit fell 23% to Rs 44.88 crore
- Revenue for Q4 FY26 rose 20.42% to Rs 578.61 crore compared to last year
- Total expenses in Q4 FY26 increased 27.36% to Rs 525.34 crore
AstraZeneca Pharma India on Tuesday reported a 23% decline in net profit to Rs 44.88 crore for the March quarter of FY26.
The company had reported a net profit of Rs 58.25 crore for the January-March quarter a year ago, according to a regulatory filing by AstraZeneca Pharma India, a biopharmaceutical company.
Its revenue climbed 20.42% to Rs 578.61 crore in the March quarter of FY26. It was Rs 480.48 crore a year ago.
Total expenses of AstraZeneca Pharma India in the March quarter grew 27.36% to Rs 525.34 crore.
For the entire FY26, AstraZeneca's net profit jumped 62% to Rs 187.52 crore.
Its total revenue rose 32.58% to Rs 2,275.58 crore for the financial year ended March 31.
The revenue growth was "supported by continued growth in Oncology and Biopharmaceuticals, as well as progress in Rare Disease", said an AstraZeneca Pharma statement.
Shares of AstraZeneca Pharma India on Tuesday closed at Rs 8,984.05 per scrip on BSE, up 2.14% from the previous close.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
